Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03585114 | Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers | active not recruiting | Phase 2 | 11 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03824275 | 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 129 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03444844 |
| Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer |
| active not recruiting |
| Phase 1 / Phase 2 |
| 60 |
| Five Eleven Pharma, Inc.INDUSTRY |
| 1 |
| May 2, 2022 |
| clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT02243033 | Phase II Laser Focal Therapy of Prostate Cancer(LITT or FLA) | active not recruiting | — | 1,000 | HALO DiagnosticsINDUSTRY | 1 | Mar 25, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | active not recruiting | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04848545 | Endocrine Disrupting Chemical Exposure and Testicular Cancer(DISRUPT) | active not recruiting | — | 700 | Rigshospitalet, DenmarkOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02490748 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer | active not recruiting | Phase 2 | 10 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02489890 | CIK in Treating Patients With Bladder Cancer | active not recruiting | Phase 2 | 1,500 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated May 11, 2022source: clinicaltrials